Shenzhen Salubris Pharmaceuticals
Shenzhen Salubris Pharmaceuticals Co Ltd is a Chinese multinational pharmaceutical and biotechnology enterprise specializing in the research, development, manufacturing, and commercialization of prescription pharmaceutical drugs, innovative biological therapeutics, and cardiovascular medical devices. The company produces advanced cardiovascular medications, anti-thrombotic drugs, orthopedic biological products, and innovative oncology drugs supplied to hospitals, clinics, and medical institutions across China and international markets. Its core business operations encompass pharmaceutical drug manufacturing, clinical trial execution, chemical synthesis, and commercial pharmaceutical distribution. Revenue is derived primarily from the wholesale sale of cardiovascular prescription drugs and biological therapeutic formulations. Shenzhen Salubris Pharmaceuticals holds a leading market position in cardiovascular pharmaceutical manufacturing in China. The company is headquartered in Shenzhen, Guangdong Province, China, and its shares trade on the Shenzhen Stock Exchange.
3 of the funds FundTelligence covers report a position in Shenzhen Salubris Pharmaceuticals.
- Legal name
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 3
Funds holding Shenzhen Salubris Pharmaceuticals
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.0 % (full portfolio disclosed, October 2026)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.0 % (full portfolio disclosed, June 2026)